Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cancer Commun (Lond) ; 42(1): 3-16, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34699693

RESUMO

BACKGROUND: Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small-scale study. Here, we conducted a multicenter, randomized, phase 3 study to compare the efficacy and safety of cisplatin plus Lipusu (LP) versus cisplatin plus gemcitabine (GP) as first-line treatment in locally advanced or metastatic LSCC. METHODS: Patients enrolled were aged between 18 to 75 years, had locally advanced (clinical stage IIIB, ineligible for concurrent chemoradiation or surgery) or metastatic (Stage IV) LSCC, had no previous systemic chemotherapy and at least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (version 1.1) before administration of the trial drug. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles. To explore the possible predictive value of plasma cytokines for LP treatment, plasma samples were collected from the LP group at baseline and first efficacy evaluation time and were then subjected to analysis by 45-Plex ProcartaPlex Panel 1 to detect the presence of 45 cytokines using the Luminex xMAP technology. The correlation between treatment outcomes and dynamic changes in the levels of cytokines were evaluated in preliminary analyses. RESULTS: The median duration of follow-up was 15.4 months. 237 patients in the LP group and 253 patients in the GP group were included in the per protocol set (PPS). In the PPS, the median PFS was 5.2 months versus 5.5 months in the LP and GP group (hazard ratio [HR]: 1.03, P = 0.742) respectively. The median OS was 14.6 months versus 12.5 months in the LP and GP group (HR: 0.83, P = 0.215). The ORR (41.8% versus 45.9%, P = 0.412) and DCR (90.3% versus 88.1%, P = 0.443) were also similar between the LP and GP group. A significantly lower proportion of patients in the LP group experienced adverse events (AEs) leading to treatment interruptions (10.9% versus 26.4%, P < 0.001) or treatment termination (14.3% versus 23.1%, P = 0.011). The analysis of cytokine levels in the LP group showed that low baseline levels of 27 cytokines were associated with an increased ORR, and 15 cytokines were associated with improved PFS, with 14 cytokines, including TNF-α, IFN-γ, IL-6, and IL-8, demonstrating an overlapping trend. CONCLUSION: The LP regimen demonstrated similar PFS, OS, ORR and DCR as the GP regimen for patients with locally advanced or metastatic LSCC but had more favorable toxicity profiles. The study also identified a spectrum of different cytokines that could be potentially associated with the clinical benefit in patients who received the LP regimen.


Assuntos
Carcinoma de Células Escamosas , Neoplasias Pulmonares , Adolescente , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma de Células Escamosas/tratamento farmacológico , Cisplatino/efeitos adversos , Desoxicitidina/análogos & derivados , Humanos , Lipossomos , Pulmão , Neoplasias Pulmonares/tratamento farmacológico , Pessoa de Meia-Idade , Paclitaxel/efeitos adversos , Adulto Jovem , Gencitabina
2.
Int J Biol Macromol ; 177: 135-148, 2021 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-33610604

RESUMO

Polylactic acid (PLA)/nano-TiO2(TiO2 NPs)/Graphene oxide (GO) nano-fibrous films were prepared by ultrasonic assisted electrostatic spinning technology, and the effects of TiO2 NPs:GO mass ratio and ultrasonic power on film morphology and mechanical, thermal, barrier and antibacterial properties were investigated. The addition of TiO2 NPs and GO can significantly increase the tensile strength and elongation at the break of PLA nano-fibrous films, and improve the water barrier properties of the nano-fibrous films. The antibacterial experiment showed that the inhibition rates of the nano-fibrous films against Escherichia coli and Staphylococcus aureus after 24 h exposure to UV irradiation reached 94.4 ± 1.8% and 92.6 ± 1.7% At the same time, the fresh-keeping packaging experiment of green peppers at room temperature, through the determination of hardness, soluble solids, chlorophyll content to determine the degree of decay of green pepper, it showed that PLA/TiO2 NPs/GO nano-fibrous films can better maintain the sensory quality of green peppers, delay the rate of spoilage of green peppers, and prolong the preservation period of green peppers.


Assuntos
Antibacterianos/química , Antibacterianos/farmacologia , Capsicum/microbiologia , Grafite/química , Nanopartículas/química , Poliésteres/química , Titânio/química , Escherichia coli/efeitos dos fármacos , Conservação de Alimentos/métodos , Nanocompostos/química , Staphylococcus aureus/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA